Linezolid vs Vancomycin: Analysis of Two Double-Blind Studies of Patients with Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia

Chest

Volumn 124, Issue 5, 2003, Pages 1789-1797

  Wunderink, Richard G ^a,e   Rello, Jordi ^b   Cammarata, Sue K ^c   Croos Dabrera, Rodney V ^c   Kollef, Marin H ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c PFIZER INC   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Methodist Healthcare   (United States)

Author keywords

Linezolid; Methicillin resistance; Nosocomial pneumonia; Regression analysis; Staphylococcus aureus; Vancomycin

Indexed keywords

AZTREONAM; LINEZOLID; METICILLIN; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GRAM POSITIVE BACTERIUM; HEART DISEASE; HOSPITAL INFECTION; HUMAN; KAPLAN MEIER METHOD; KIDNEY DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MORBIDITY; MULTICENTER STUDY; NOSOCOMIAL PNEUMONIA; OUTCOMES RESEARCH; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0242552187     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.5.1789     Document Type: Article

References (31)

1. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000; 21:510-515
2. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study; EPIC International Advisory Committee. JAMA 1995; 274:639-644
3. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-412
4. Wunderink RG, Cammarata SK, Oliphant TH, et al. Linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia: continuation of a randomized, double-blind, multicenter study. Clin Ther 2003; 25:980-992
5. Cammarata SK, Wunderink RG, Timm JA, et al. Efficacy of linezolid in patients with nosocomial pneumonia based on severity of illness as determined by baseline APACHE score: Interscience Conference on Antimicrobial Agents and Chemotherapy 2000; 40:487; Poster 2234
6. Cammarata SK, Hempsall KA, Oliphant T. Linezolid in nosocomial pneumonia: efficacy results by severity of illness as determined by APACHE II scores [abstract] Chest 2001; 120(4 Suppl):168S
7. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: nosocomial pneumonia; developing antimicrobial drugs for treatment, 1998. Available at: http://www.fda.gov/cder/guidance/2571dft.pdf. Accessed October 8, 2003
8. Fagon J, Patrick H, Haas DW, et al. Treatment of Gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/ dalfopristin versus vancomycin; Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161:753-762
9. Fagon JY, Chastre J, Domart Y, et al. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996; 23:538-542
10. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996; 275:134-141
11. Ibrahim EH, Ward S, Sherman G, et al. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000; 117:1434-1442
12. Ibrahim EH, Tracy L, Hill C, et al. The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest 2001; 120:555-561
13. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001; 120:1883-1887
14. Timsit JF, Chevret S, Valcke J, et al. Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic tools. Am J Respir Crit Care Med 1996; 154:116-123
15. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474
16. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22:387-394
17. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:196-200
18. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-1490
19. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38:865-869
20. Conte JE Jr., Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46:1475-1480
21. Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid [abstract]. Chest 2002; 122(4 Suppl): 159S
22. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281-286
23. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18:533-543
24. Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994; 18:544-546
25. Karam CM, McKinnon PS, Neuhauser MM, et al. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 1999; 19:257-266
26. Tobin CM, Darville JM, Thomson AH, et al. Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J Antimicrob Chemother 2002; 50:713-718
27. Gilbert DN, Moellering RC, Jr, Sande MA. The Sanford Guide to Antimicrobial Therapy. Hyde Park, VT: Antimicrobial Therapy, 2001; 1-142
28. Schentag JJ. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother 1999; 11:426-439
29. Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000; 57(Suppl 2):S4-S9
30. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 150:1545-1549
31. Pujol M, Corbella X, Pena C, et al. Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17:622-628